Lehigh Valley Office Update

Genetic Testing (PGT-A)

At RMA, we know that Pre-Implantation Genetic Testing for Aneuploidy (PGT-A) can give hopeful parents unparalleled peace of mind. When paired with In Vitro Fertilization (IVF), it further ensures that only the healthiest embryo is implanted at a time.

genetic testing pgt-a

What is PGT-A?

Genetic testing, as part of fertility treatment, can improve the chance of success, potentially reduce time in care, and provide patients and their care team with powerful information for supporting a healthy pregnancy and delivery.

What is PGT-A?

RMA uses the most advanced PGT-A platform available to screen embryos for genetic abnormalities.

Validated over several years and multiple rigorous clinical trials, the PGT-A platform can accurately determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy) with more precision than the vast majority of other platforms. This is important because published data suggests 50-70% of miscarriages are due to aneuploidy. Selection with PGT-A can substantially reduce these risks.

infertility nursing staff
reproductive medicine research

Purpose of Testing

  • Allows the embryologist to accurately select the highest quality embryo for transfer
  • Selecting high-quality embryos improves implantation rates and reduces miscarriage rates
  • Greatly increases the effectiveness of Single Embryo Transfer (SET)
  • Reduces the risks associated with becoming pregnant with multiples. These risks include increased risk of premature birth and low birth weight babies, increased risk of C-section and time spent in neonatal intensive care units, as well as health risks to the mother.

Interpreting Results

Women who have three chromosomally-normal embryos as a result of In Vitro Fertilization (IVF) have a 94.9% chance of achieving pregnancy, new research conducted by Reproductive Medicine Associates (RMA) and presented at the annual meeting of the American Society for Reproductive Medicine (ASRM) shows.

To begin aneuploidy screening with PGT-A, a sample is biopsied (safely removed) from an embryo. The method of biopsy used in PGT-A has been determined to be the safest available. Approximately five cells are removed from a specific area of the embryo called the trophectoderm at a specific time in embryonic development.

Unlike other methods of biopsy, a trophectoderm biopsy has no significant impact on the reproductive potential of the embryo and therefore maximizes the benefit of PGT-A. The biopsied cells are then sent to the Foundation for Embryonic Competence, where they are analyzed. About seven days later, a report is sent to your IVF team. Once the PGT-A report comes in, we will notify you to review the results.

local fertility clinic

Speak to a Fertility Specialist & Get Started

Begin Your Family Building Journey
Give Us a CallMake An Appt

Florida: 407-804-9670

Lehigh Valley (Existing Patients): 610-820-6888

Lehigh Valley (New Patients): 973-656-2089

New Jersey (Existing Patients): 973-971-4600

New Jersey (New Patients): 973-656-2089

Northern California: 415-603-6999

Philadelphia: 215-654-1544

Southern California: 424-293-8841